[Research progress in drugs targeting 5-lipoxygenase for age-related diseases].
Sheng Li Xue Bao
; 75(6): 864-876, 2023 Dec 25.
Article
em Zh
| MEDLINE
| ID: mdl-38151349
ABSTRACT
With the acceleration of aging society, delaying aging or promoting healthy aging has become a major demand for human health. 5-Lipoxygenase (5-LOX) is a key enzyme catalyzing arachidonic acid into leukotrienes (LTs), which is a potent mediator of the inflammatory response. Previous studies showed that abnormal activation of 5-LOX and overproduction of LTs are closely related to the occurrence and development of aging-related inflammatory diseases. Therefore, inhibiting 5-LOX activation is a possibly potential strategy for treating age-related diseases. In this paper, the latest research progress in 5-LOX activation, 5-LOX in mediating aging-related diseases and its small molecule inhibitors is briefly reviewed to provide scientific theoretical basis and new ideas for the prevention and treatment of aging-related inflammatory diseases.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Araquidonato 5-Lipoxigenase
/
Leucotrienos
Idioma:
Zh
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
China